Highlights from the SMA Europe June 2026 newsletter, tracked here as external landscape — not platform results.

Clinical landscape (external programs)

• Ignaseclant (NMD670, NMD Pharma) — a ClC-1 / CLCN1 skeletal-muscle chloride-channel inhibitor aimed at improving muscle function alongside SMN-restoring therapy. The Phase 2 SYNAPSE-SMA trial (52 ambulatory adults) has completed; results expected summer 2026.
• Apitegromab (Scholar Rock) — an anti-myostatin (MSTN/GDF8) muscle-mass adjunct. FDA BLA accepted (decision by 30 Sep 2026); EMA review ongoing (~mid-2026); the OPAL trial is recruiting children aged 2 years or younger.
• Access: NICE recommended permanent NHS England funding for nusinersen and risdiplam.

Why these are not in our compute queue

This platform exists to surface novel, unvalidated computational hypotheses. ClC-1 and myostatin are already in late-stage clinical validation by their sponsors, so re-running docking on them would add no value. We track them here as landscape context instead — see the Drugs & Therapies page (tier: Investigational for SMA).

New literature added to our tracker

Eleven recent SMA papers (fundamental research, clinical, and reviews) were added to the Literature graph, including Bon et al. (flunarizine alters miRNA in SMA models, Sci Rep), Sun et al. (non-cell-autonomous mechanisms & systemic interactions, Am J Pathol), Gopi et al. (epigenetic contributors to phenotype variability, Neuroscience), and AAV9-SMN1 gene-therapy comparisons (Chen et al., Nat Commun; Yu et al., Mol Ther).

Source: SMA Europe monthly newsletter, June 2026. All items are external literature/clinical programs, not computational results from this platform.